Traitement Ostéosarcome en Israël — recevez 3 correspondances personnalisées de cliniques

Osteosarcoma treatment in Israel follows a rigorous three-stage protocol involving neoadjuvant chemotherapy, limb-sparing surgical resection, and adjuvant chemotherapy. Specialist centers like Sourasky Medical Center and Sheba Medical Center prioritize tumor shrinkage with aggressive drug regimens. This approach enables a 95% success rate for limb-salvage procedures.

• Neoadjuvant phase: High-dose chemotherapy shrinks tumors over 10 weeks to enable safer limb-sparing surgery.
• Surgical resection: Surgeons remove the tumor while preserving the limb using endoprostheses or grafts.
• Adjuvant phase: Post-operative chemotherapy continues for 4 to 9 months to eliminate residual cells.
• Precision monitoring: Scans occur every 3 months post-treatment to monitor for potential lung recurrence.

Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center offer highly specialized pediatric-specific protocols that are not available at every general hospital. For example, their allogeneic bone marrow transplant package for pediatric osteosarcoma includes a 30-day hospital stay. This level of intensive inpatient monitoring is a critical differentiator for high-risk childhood cases compared to standard outpatient chemo cycles.

Patient Consensus: Patients note that the recovery phase after limb-salvage surgery is physically demanding. They emphasize the importance of requesting a fertility preservation consultation before starting the first round of aggressive chemotherapy.

Israeli surgeons perform limb-preserving surgery for 90% to 95% of osteosarcoma cases. These procedures prioritize tumor removal while maintaining functional use of the arm or leg. Specialists integrate 3D-modeled implants and navigation-guided resections. This approach successfully replaces amputation as the primary treatment standard.

• Advanced reconstruction: Surgeons use patient-specific 3D titanium implants and customized surgical guides.
• Pediatric innovation: Expandable mega-prostheses grow with children via remote magnetic control units.
• Surgical precision: Computer-assisted navigation and robotic platforms enable precise, negative-margin tumor resections.
• Biological grafting: Techniques include vascularized fibula grafts and recycled bone for natural tissue reconstruction.

Bookimed Expert Insight: Israeli orthopedic oncology units, like the one at Sourasky Medical Center active since 1995, manage massive patient volumes exceeding 1.8 million annually. This high frequency allows centers to maintain unique sub-specialties specifically for pediatric bone tumors. For example, Dr. Dror Levin combines oncology with specialized training from Italy’s Rizzoli Institute. Such concentrated expertise is rare and ensures that even complex cases in growing children benefit from the most specialized limb-salvage protocols available globally.

Patient Consensus: Patients note it is important to choose centers that provide multidisciplinary teams, specifically highlighting how orthopedic and plastic surgeons work together. Many mention the relief of avoiding repeated surgeries for children thanks to the remotely adjustable growing implants.

Advanced systemic therapies for metastatic or relapsed osteosarcoma in Israel focus on personalized immunotherapy and targeted drug protocols. Leading facilities like Sheba Medical Center and Sourasky Medical Center provide CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and precision tyrosine kinase inhibitors. These treatments aim to stabilize disease and improve survival.

• Immunotherapy options: Advanced centers offer CAR-T, TIL therapy, and checkpoint inhibitors like Pembrolizumab.
• Targeted agents: Tyrosine kinase inhibitors including Cabozantinib and Regorafenib target critical molecular pathways.
• Bone-targeted therapy: Denosumab and radionuclide treatments help manage skeletal lesions and preserve bone.
• Cellular treatments: Allogeneic bone marrow transplantation is available for high-risk pediatric cases.
• Second-line chemotherapy: Combinations of Gemcitabine with Docetaxel or Ifosfamide are standard regimens.

Bookimed Expert Insight: Israeli oncology centers like Sourasky report a 90% success rate in general oncology treatments. This is driven by deep specialization in rare subtypes. For example, Dr. Ofer Merimsky has over 40 years of experience specifically in sarcomas. Clinicians here often lead clinical trials for targeted drugs like Lenvatinib before they become global standards. This provides patients with access to therapies that are not yet available in many other countries.

Patient Consensus: Patients emphasize the importance of requesting Next-Generation Sequencing (NGS) tumor profiling early to identify targeted drug options. Families note that compassionate use programs at hospitals like Sheba can provide access to experimental combinations when standard chemotherapy fails.

Israel hosts globally recognized bone sarcoma centers including Sheba Medical Center, Sourasky Medical Center, and Rambam Health Care Campus. Most facilities hold JCI accreditation and rank among Newsweek’s top medical institutions. These centers specialize in limb-salvage surgery and innovative targeted immunotherapies for osteosarcoma.

• Sheba Medical Center: Ranked 7th worldwide by Newsweek and treats over 2 million patients annually.
• Sourasky Medical Center: Operates the National Center for Sarcomas with a 90% oncology success rate.
• Rambam Healthcare Campus: Serves as the primary referral center for advanced surgical oncology in northern Israel.
• Specialized expertise: Prof. Ofer Merimsky at Sourasky has over 40 years of bone sarcoma experience.

Bookimed Expert Insight: While many search for general oncology, the most successful outcomes in Israel occur at centers with dedicated orthopedic oncology units. For example, Sourasky Medical Center has a specialized Head of Metastatic Bone Lesions, Dr. Jakov Bikels. This granular specialization ensures that complex reconstructive surgeries happen alongside tumor removal rather than as a secondary concern.

Patient Consensus: Patients note that the professionalism and expertise of doctors like Dr. Dror Levin provide a pleasant experience. They recommend confirming if an integrated protocol including pathology and limb-salvage surgery is available before traveling.

Limb-salvage surgery in Israel typically requires a 7 to 10 day hospital stay. Patients often stand within 2 to 3 days using assistive devices. Specialized inpatient rehabilitation usually lasts 10 days. Full functional recovery for osteosarcoma patients may extend from 6 months to 1 year.

• Early mobilization: Most patients begin walking with crutches 48 to 72 hours after surgery.
• Inpatient phase: Dedicated rehabilitation centers like Sheba Medical Center provide 10 days of intensive care.
• Outpatient recovery: Basic function is achieved in 3 to 6 months with consistent physiotherapy.
• Full restoration: Nerve and bone regeneration can take up to 12 months for optimal results.

Bookimed Expert Insight: Israeli oncology centers like Sourasky or Sheba often integrate orthopedic surgeons directly into oncology teams. This allows patients to bypass local specialized rehab wait times. By choosing a facility with an onsite rehabilitation department, you can consolidate surgical follow-ups and intensive therapy in one city. This frequently shortens the non-weight-bearing phase by 1 to 2 months compared to fragmented care models.

Patient Consensus: Patients emphasize that rehabilitation is a long process requiring persistence and 3 weekly sessions. Many note that preparing for a 9 month non-weight-bearing period is helpful for mental and logistical readiness.